Barrington Research Has Negative Outlook of MMSI Q2 Earnings

Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) - Equities researchers at Barrington Research lowered their Q2 2025 earnings per share estimates for shares of Merit Medical Systems in a research report issued on Friday, April 25th. Barrington Research analyst M. Petusky now anticipates that the medical instruments supplier will post earnings per share of $0.88 for the quarter, down from their prior estimate of $1.03. Barrington Research currently has a "Outperform" rating and a $103.00 price objective on the stock. The consensus estimate for Merit Medical Systems' current full-year earnings is $3.37 per share. Barrington Research also issued estimates for Merit Medical Systems' Q3 2025 earnings at $0.80 EPS, Q4 2025 earnings at $0.80 EPS, Q1 2026 earnings at $0.81 EPS, Q2 2026 earnings at $1.05 EPS, Q3 2026 earnings at $0.91 EPS, Q4 2026 earnings at $0.94 EPS and FY2027 earnings at $4.05 EPS.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last announced its earnings results on Thursday, April 24th. The medical instruments supplier reported $0.86 earnings per share for the quarter, topping analysts' consensus estimates of $0.75 by $0.11. Merit Medical Systems had a net margin of 9.05% and a return on equity of 15.61%. The company had revenue of $355.35 million during the quarter, compared to the consensus estimate of $352.57 million. During the same period in the previous year, the firm posted $0.77 earnings per share. The company's revenue was up 9.8% on a year-over-year basis.

Several other research firms have also weighed in on MMSI. Piper Sandler reduced their target price on Merit Medical Systems from $116.00 to $112.00 and set an "overweight" rating on the stock in a report on Wednesday, April 23rd. Needham & Company LLC lowered their target price on Merit Medical Systems from $116.00 to $100.00 and set a "buy" rating for the company in a research note on Friday, April 25th. Raymond James reduced their price objective on Merit Medical Systems from $116.00 to $108.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. JPMorgan Chase & Co. assumed coverage on Merit Medical Systems in a research note on Friday, March 28th. They issued an "overweight" rating and a $120.00 target price on the stock. Finally, Robert W. Baird lowered their price objective on shares of Merit Medical Systems from $111.00 to $110.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $107.78.

Merit Medical Systems Trading Down 0.3 %

Merit Medical Systems stock traded down $0.31 during mid-day trading on Monday, hitting $94.45. The stock had a trading volume of 595,062 shares, compared to its average volume of 502,447. The company has a current ratio of 5.36, a quick ratio of 3.82 and a debt-to-equity ratio of 0.57. Merit Medical Systems has a 12 month low of $73.67 and a 12 month high of $111.45. The stock has a market capitalization of $5.58 billion, a PE ratio of 46.30, a P/E/G ratio of 2.34 and a beta of 0.85. The stock has a 50-day simple moving average of $98.16 and a two-hundred day simple moving average of $100.56.

Insider Buying and Selling at Merit Medical Systems

In other news, CFO Raul Jr. Parra sold 12,451 shares of Merit Medical Systems stock in a transaction on Friday, February 28th. The stock was sold at an average price of $98.81, for a total transaction of $1,230,283.31. Following the completion of the sale, the chief financial officer now owns 24,201 shares of the company's stock, valued at approximately $2,391,300.81. This trade represents a 33.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Brian G. Lloyd sold 25,000 shares of the firm's stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $99.50, for a total value of $2,487,500.00. Following the completion of the sale, the insider now directly owns 38,993 shares in the company, valued at $3,879,803.50. This trade represents a 39.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 109,132 shares of company stock valued at $11,139,521 in the last quarter. 3.70% of the stock is currently owned by insiders.

Institutional Trading of Merit Medical Systems

Several institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Merit Medical Systems by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 6,648,659 shares of the medical instruments supplier's stock valued at $643,058,000 after buying an additional 63,314 shares during the period. FMR LLC boosted its holdings in Merit Medical Systems by 31.6% in the fourth quarter. FMR LLC now owns 2,076,439 shares of the medical instruments supplier's stock valued at $200,833,000 after acquiring an additional 499,193 shares during the last quarter. Fuller & Thaler Asset Management Inc. increased its position in Merit Medical Systems by 2.3% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 1,633,246 shares of the medical instruments supplier's stock valued at $157,968,000 after purchasing an additional 36,489 shares during the period. Invesco Ltd. raised its holdings in Merit Medical Systems by 8.3% during the 4th quarter. Invesco Ltd. now owns 1,535,468 shares of the medical instruments supplier's stock worth $148,510,000 after purchasing an additional 118,142 shares during the last quarter. Finally, Royal Bank of Canada lifted its position in shares of Merit Medical Systems by 0.6% in the 4th quarter. Royal Bank of Canada now owns 938,210 shares of the medical instruments supplier's stock worth $90,744,000 after purchasing an additional 5,932 shares during the period. Institutional investors own 99.66% of the company's stock.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.